| Project/Area Number |
09557052
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KAWATA Sumio Osaka University Medical School, Associate professor, 医学部, 助教授 (90183285)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
木曽 真一 大阪大学, 医学部・附属病院, 医員
FUKUDA Kazuto Osaka University Hospital, Medical Staff, 医学部・附属病院, 医員
TAMURA Shinji Osaka University Medical School, Associate professor, 医学部, 助手 (30243223)
KISO Shinich Osaka University Hospital, Medical Staff
松田 幸彦 大阪大学, 医学部, 助手 (90283770)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
Fiscal Year 1997: ¥3,300,000 (Direct Cost: ¥3,300,000)
|
|---|
| Keywords | TGF-b / plasma TGF-b1 / TGF-b receptor / anti-TGF-b therapy / TGF-βレセプター |
|---|
| Research Abstract |
We have reported that TGF-bl is produced by human hepatocellular carcinoma and colon cancer and that plasma TGF-bl concentration is elevated in patients with these cancers. The circulated TGF-b1 contributed to reduced anti-tumor immunity and enhanced vascularity in the timors.
Our hypothesis is that the circulating TGF-bl may contribute to prognosis of the patients. We divided 70 patients with hepatocellular carcinoma into a group with high concentration of plasma TGF-IA (more than 8.7 ng/ml) and a group with low concentration (below 8.7). The survival time was short in the group with high concenteration. This result was confirmed in each tumor stage. Cox proportional-hazard regression analysis showed that plasma TGF-bl concentration is a risk factor contributing for the prognosis.
We also are studying on anti-tumor effect of recombinant soluble form TGF-b receptor type II against human hepatoma transplanted in nude mice. These experiments may lead to anti-TGF-b therapy in human cancer patients.
|
